Amyotrophic Lateral Sclerosis by David S. Shin et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
20 
Amyotrophic Lateral Sclerosis 
David S. Shin1, Ashley J. Pratt2,  
Elizabeth D. Getzoff2 and J. Jefferson P. Perry2,3  
1Lawrence Berkeley National Laboratory, 
2The Scripps Research Institute, 
3Amrita University,  
1,2USA 
3India 
1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative motor neuron disease for 
which no successful treatment presently exists. ALS is also termed Charcot’s disease 
(maladie de Charcot), after the French clinician Jean Martin Charcot who first described its 
features in 1869 (Charcot 1869) or Lou Gehrig’s disease in the United States, after the New 
York Yankees baseball player afflicted with the condition. Within Europe ALS is often 
referred to as Motor Neuron Disease, describing the cells chiefly affected, although this term 
may also more generally refer to a wider group of motor neuron diseases. 
ALS is characterized by the degeneration of motor cortex, brainstem and/or motor neurons 
associated with the spinal cord, resulting in muscle weakness and loss of voluntary muscle 
control. Progressive paralysis ensues, and respiratory failure is the usual cause of death. 
Amyotrophic refers to the lack (a-) of muscle (-myo-) nourishment (-trophic), resulting in 
wasting of the fibers; Lateral refers to the lateral corticospinal tract of affected neurons 
between the brain and spinal cord; Sclerosis is the resultant hardening of the tissue. The 
incidence of ALS globally ranges from 0.3 to 2.4 cases per 100,000 (Sathasivam 2010). 
Approximately 95% of ALS cases are random or sporadic (SALS), whereas 5 or more percent 
are inherited (familial ALS, FALS), with a subset of these arising from known genetic 
determinants. 
Despite the initial description of the disorder about 150 years ago, and significant progress 
in the understanding of its pathology, ALS remains an ill-defined terminal disease with few 
medicinal options and an average duration of only a few years. Nonetheless, new 
developments in ALS research are slowly emerging in diagnostics, in elucidating molecular 
mechanisms behind the disease, and in generating treatments. Improved technologies and 
recent research insights, when coupled with meaningful collaborations between scientists 
and clinicians hold promise for exciting progress. Thus, we discuss here the current 
understanding of ALS in terms of its clinical presentation, and its molecular and cellular 
basis. In particular, we highlight new insights into the genetics of the inherited disease, with 
a focus on the mutant gene products Cu,Zn-superoxide dismutase (Cu,ZnSOD), Fused in 
Sarcoma/Translated in Lipsarcoma (FUS/TLS) and the Tar-DNA binding protein 43 (TDP-
43). The standard care regimen will also be described, along with a focus on novel 
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therapeutic strategies and developments for improving the outlook for patients with this 
terminal disease. 
2. Clinical phenotype 
The initial onset of ALS (both FALS and SALS) typically begins with one of several patterns. 
Seventy five percent of patients have “spinal onset,” affecting the limbs (Kiernan et al. 2011). 
Within this group a “cervical” subset will have muscle weakness in the upper limbs, while 
symptoms of the “lumbar” subset will arise in the lower limbs. In ALS, affected cells include 
the upper motor neurons (UMN) in the motor cortex and/or lower motor neurons (LMN) in 
the brainstem and spinal cord. Presentation of pure UMN symptoms, sometimes referred to 
as primary lateral sclerosis (PLS), includes decelerated speech, weakness and spasticity, 
hypereflexia, pseudobulbar affect (inappropriate emotionality including bursts of crying or 
laughing). Presentation of pure LMN symptoms, known as progressive muscular atrophy 
(PMA), includes severe weakness and hypereflexia, in addition to loss of muscle tone, muscle 
atrophy, cramps and twitching (termed fasciculations) (Sathasivam 2010; Lomen-Hoerth 2008). 
A combination of UMN and LMN symptoms may also occur. Onset is usually asymmetrical, 
although progressive wasting and spreading will most likely ensue (Swash 1998).  
Fewer patients have “bulbar onset” ALS, which targets muscles of the face and neck; this 
form is more common in women and the elderly (Forbes, Colville, and Swingler 2004; 
McCombe and Henderson 2010) and has a worse prognosis. Symptoms of the UMN-based 
bulbar variant (pseudobulbar palsy) include emotional responses (as mentioned above), 
slurred speech (dysarthria), excessive yawning and jerking of the jaw (Wicks 2007; Kuhnlein 
et al. 2008). The LMN-based affliction (bulbar palsy) manifests as tongue fasciculation 
resulting in dysarthria, drooling, difficulties in swallowing (dysphagia) and wasting of the 
tongue (Kuhnlein et al. 2008). Several rare, additional phenotypes exist, including a 
respiratory onset form, which shares the poorest prognosis with the bulbar onset form (Chio 
et al. 2011). 
The characteristic clinical course of ALS is a progressive loss of voluntary movement, with 
symptoms spreading to more distant locations (Haverkamp, Appel, and Appel 1995), and 
the end result being paralysis and death from respiratory failure. Treatment with a 
ventilator may assist breathing and improve the quality of life (Radunovic et al. 2009). 
However, eventually the patient may enter a “locked-in“ state, where communication is 
only possibly with the help of an electronic device, and ultimately, even oculomotor 
function may be impaired (Sharma et al. 2011). In addition to facial, limb and behavioral 
impairments, frontotemporal dementia (FTD) occurs in a subset of ALS patients (Murphy, 
Henry, and Lomen-Hoerth 2007), with negative implications for treatment and survival 
(Olney et al. 2005). Frontotemporal dementia (FTD) patients can also display ALS-like 
symptoms, suggesting that some aspects of these two diseases may overlap (Ferrari et al. 
2011). Unfortunately, treatment of ALS is mostly palliative; the sole approved drug, riluzole 
(as discussed in section 4), extends life for only a few months (Miller et al. 2007). Typically, 
half of diagnosed ALS patients will succumb to the disease within about 3 years, 20-25% 
within 5 years and a small minority can survive 10 years and beyond (Talbot 2009; Testa et 
al. 2004; Forsgren et al. 1983). Post-mortem staining of the degenerating tissues in motor 
neurons of the motor cortex, brainstem and spinal cord with eosin and hematoxylin may 
reveal Bunina bodies and/or ubiquitin-positive-inclusions of the skein-like or hyaline form 
(most commonly the Lewy body-like variety), among others (Leigh et al. 1991). Thus, the 
underlying multi-pathway cellular dyshomeostasis leading to the complicated, heterogeneous 
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clinical phenotypes associated with ALS and its variants so far remains mysterious and is 
under intense investigation. 
The distinction between familial and sporadic cases of ALS is not always clear-cut, due to 
incomplete genetic penetrance, complicating environmental factors and diagnostic 
difficulties. FALS has been attributed to approximately 5% of ALS cases (Byrne and 
Hardiman 2010; Talbot 2010), although higher levels in certain geographical regions have 
been reported (Haberlandt 1959; Murros and Fogelholm 1983). It has been suggested that 
even rates for the familial disease as high as 13.5% might be underestimates (Andersen 
2006), due to the complicating variable of reduced penetrance in some families, causing 
miscategorization of some FALS cases as SALS (Williams, Floate, and Leicester 1988). FALS 
is usually inherited in a Mendelian, autosomal dominant manner (Veltema, Roos, and Bruyn 
1990), with autosomal recessive and X-linked modes of inheritance occurring rarely 
(Donkervoort and Siddique 1993; Andersen et al. 1996). The clinical symptoms of FALS and 
SALS are generally similar, but may be more homogeneous within individual FALS-
afflicted families than between them (Horton, Eldridge, and Brody 1976). The mean age of 
onset at about 48-52 years for FALS (Mulder et al. 1986; Li, Alberman, and Swash 1988) is 
earlier than the mean at approximately 56 years for SALS (Li, Alberman, and Swash 1988; 
Haverkamp, Appel, and Appel 1995) and the survival period is also shorter for FALS than 
for SALS (Mulder et al. 1986). A small minority of ALS patients exhibit juvenile onset 
(usually before age 25), which is generally characterized by longer survival (Aggarwal and 
Shashiraj 2006; Ben Hamida, Hentati, and Ben Hamida 1990). Juvenile-onset ALS can occur 
in an autosomal dominant form, linked to several known genes (Blair et al. 2000) or in a 
form that may be recessive or sporadic (Hadano et al. 2001). 
The lifetime risk of ALS is about 1 in 400, [in the United Kingdom (Alonso et al. 2009)], yet 
due to the very short survival rate of about 3 years (Donkervoort and Siddique 1993), the 
disease prevalence is low, ranging from only 0.8 per 100,000 people (in Mexico) to 8.4 per 
100,000 (in Sweden) (Olivares, Esteban, and Alter 1972; Gunnarsson and Palm 1984). The 
yearly incidence of ALS globally varies only slightly worldwide, from as few as 0.3 
diagnoses per 100,000 persons in Hong Kong-China (Fong et al. 1996) to 2.4 cases per 
100,000 in Finland (Fong et al. 1996), excepting a few, documented, high-occurrence clusters 
[e.g. an ALS-Parkinsonism-like disease frequency in Guam of up to 100 times greater than 
average in the middle of the 20th century (Steele and McGeer 2008)]. More studies of non-
Caucasian populations are needed to evaluate ALS rates across all ethnic groups (Cronin, 
Hardiman, and Traynor 2007). The gender ratio for ALS varies somewhat between studies, 
and with factors such as age and ethnicity (McCombe and Henderson 2010; Abhinav et al. 
2007) but consistently shows an increased risk for males. This variability may be due to 
regional, environmental or genetic differences among patients or, to a decrease in the 
skewing of ALS cases toward men over time (Worms 2001). Interestingly, the ratio also 
tends more toward gender equality in FALS than in SALS (Mulder et al. 1986; Li, Alberman, 
and Swash 1988).  
No diagnostic test for ALS is currently available. The Revised El Escorial criteria (Brooks et 
al. 2000), developed by the World Federation of Neurology, are a set of findings used in the 
diagnosis of ALS. They categorize the case as “definite,“ “probable“ or “possible,“ based on 
clinical UMN and LMN observations and electrophysiological data. These criteria are 
commonly used for participation in clinical trials, although they have been suggested to be 
inappropriate for general clinical practice (Andersen et al. 2005) and not sensitive enough as 
an early diagnostic tool (Kiernan et al. 2011). Earlier diagnosis is in fact highly associated 
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with a longer survival (Testa et al. 2004; Haverkamp, Appel, and Appel 1995), although the 
median duration between first symptoms and diagnosis was found to be about a year for 
many cases (Chio 1999; Spuler et al. 2011). Another measure sometimes used in research or 
private practice is the revised ALS Functional Rating Scale (ALSFRS-R), a scoring tool to 
monitor the disease progression of patients (Cedarbaum et al. 1999). These measures and 
others [e.g. the Awaji criteria, (de Carvalho et al. 2008)] are undoubtedly useful. However, 
objective laboratory tests (e.g. for ALS-specific blood or cerebrospinal fluid biomarkers) 
would represent a major stride in diagnosis, and some progress is underway in this area 
(Turner et al. 2009), though validation is still needed. 
Current diagnosis of ALS is typically by process of elimination. The trained clinician will 
assess the presence of UMN and/or LMN symptoms and any evidence of disease 
progression, then test to eliminate potentially overlapping syndromes. For FALS, the 
presence of an affected family member can aid diagnosis, and trigger genetic testing, if 
appropriate (Andersen 2000). Due to the heterogeneity of presentation (Chio et al. 2011), the 
exclusion of ALS mimics is a very important part of diagnosis. Conditions with overlapping 
symptoms may include spinal disease or injury (e.g. compression), enzyme or vitamin 
deficiency (B-12 etc.), cancers, myopathy, neuropathy, infections such as Lyme or HIV, 
thyroid problems, myasthenia gravis, Kennedy’s disease, Tay-Sachs diseases, lead poisoning 
and multiple sclerosis, among others (Sathasivam 2010; Lomen-Hoerth 2008; Traynor et al. 
2000; Silani et al. 2011). Elimination of these ALS mimics is non-trivial, especially since 
misdiagnosis is very common (Chio 1999; Traynor et al. 2000). Conversely, false positive 
diagnosis of ALS (estimated at around 10%) can also have marked impacts on patient 
prognosis and treatment (Davenport et al. 1996; Ludolph and Knirsch 1999). Magnetic 
resonance imaging (MRI) is one of the most commonly performed diagnostic tests to image 
the condition of the brain and neck, to eliminate injury as a cause of symptoms. 
Electromyography (EMG) and nerve conduction studies are useful for evaluating muscle 
and nerve status. Blood tests (to determine blood count, erythrocyte sedimentation, specific 
enzyme abnormalities such as creatine kinase) are also useful (Talbot 2009). Less commonly, 
CSF tests, psychological tests and muscle biopsies are performed to rule out other 
conditions. Therefore, diagnosis is made by careful examination of the clinical presentation 
coupled to evaluation by laboratory tests.  
3. Pathophysiology 
Despite a multitude of genetic, biochemical, cellular and clinical investigations, current ALS 
research suggests that there is no definitive single cause for the disease and/or that the 
cellular pathways involved employ much complexity. Thus, further research is required on 
all fronts to elucidate the underlying pathophysiological mechanisms. We focus on several 
key disease-implicated proteins, and discuss advances and controversies in our 
understanding of how mutations may give rise to the disease. We include our own studies 
on ALS-linked mutations in Cu,Zn superoxide dismutase (SOD), which account for a very 
significant proportion of genetically defined FALS cases. We also address other genetic 
factors and environmental influences that have been implicated in ALS.  
3.1 Genetic factors 
Many recent significant advances in ALS research result from investigations of genetic 
lesions and their consequent biological defects leading to the disease. Most of these genetic  
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abnormalities in ALS alter expressed proteins through missense and nonsense mutations, 
but some genetic linkages are presently not yet connected to a specific underlying protein 
defect. ALS cases arising from genetic defects have been further divided into subtypes 
dependent on gene mapping, linkage analysis and phenotype (Table 1). The more 
characterized subtypes are referred to as ALS1 through ALS14. We have also included in 
Table 1 several other genes implicated in ALS susceptibility (Al-Chalabi et al. 1999; He and 
Hays 2004; Munch et al. 2005; Munch et al. 2004). Below, we describe the distribution of 
>130 distinct mutations in ALS1 (Cu,ZnSOD) within the protein structure, and provide 
current hypotheses for how this multitude of distinct substitutions affect Cu,ZnSOD 
structure and function, leading to an ALS phenotype. We also focus on proteins involved in 
predominately sporadic ALS cases. In particular, we highlight recent results that point to 
mutation-induced dysfunctions of ALS6 (FUS/TLS) and ALS10 TDP-43 (also involved in 
certain familial ALS cases), two proteins that are involved in DNA/RNA synthesis and gene 
regulation, implicating a role for RNA metabolic defects in the disease. 
 
 
Table 1. ALS subtypes. ALS phenotypes map to many chromosomal loci, and often to specific 
proteins implicated in the disease. Data for this table were compiled from the Online 
Mendelian Inheritance in Man® (MIM) website (http://omim.org) and other sources 
(Pasinelli and Brown 2006; Ticozzi et al. 2011; Boillee, Vande Velde, and Cleveland 2006; 
Deng et al. 2011) MIM gene and phenotype numbers are included for reference. Abbreviations 
in Notes column: AD, autosomal dominant; AR, autosomal recessive; Sp, sporadic; Suscept, 
aids susceptibility to ALS; X-linked, Chromosome X linkage 
3.1.1 Cu,Zn superoxide dismutase 
Cu,ZnSOD was first isolated from bovine erythrocytes in the late 1930s (Mann and Keilin 
1938). The protein was then termed hemocuprein for its copper content, apparent from the 
blue color of the crystalline protein. In the 1950s, Cu,ZnSOD was purified from brain (Porter 
and Folch 1957), where it accounts for approximately 1% of neuronal cytosolic protein 
(Siddique and Deng 1996). McCord and Fridovich biochemically characterized the protein in 
1969, and discovered that it catalyzed the dismutation of superoxide radicals to hydrogen 
peroxide and oxygen (McCord and Fridovich 1969). Reactive oxygen species, such as 
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superoxide, were subsequently linked to aging and to many diseases. This cytosolic protein 
was discovered to be unusually stable, surviving organic extraction in the original 
purifications (McCord and Fridovich 1969) and maintaining enzymatic activity under harsh 
conditions, such as denaturants and heat (Forman and Fridovich 1973; Malinowski and 
Fridovich 1979; Hallewell et al. 1991). Our labs routinely use heat denaturation of host 
proteins when purifying Cu,ZnSOD from heterologous expression systems (Shin et al. 2009). 
This unusual enzymatic stability could be involved ALS etiology. 
Members of our groups have analyzed the biochemical, biophysical and structural 
properties of wild-type and ALS-linked mutant Cu,ZnSOD proteins. The first Cu,ZnSOD X-
ray crystal structure (Tainer et al. 1982; Tainer et al. 1983), revealing the fold and structure-
based mechanism of catalysis, was from the bovine enzyme and was later followed by our 
crystal structure of human Cu,ZnSOD (Figure 1) (Parge, Hallewell, and Tainer 1992). 
 
 
Fig. 1. Human Cu,ZnSOD crystal structure (PDB ID 1PU0) and known ALS mutation sites. 
Cu,ZnSOD exists as a homodimer and each subunit consists of a single Greek-key motif 
barrel-like domain, flanked by extended loops that form the active site cleft and house 
catalytic Cu and Zn ions (large labeled spheres). The smaller red spheres denote Cα ALS 
mutation site positions mapped onto this cartoon representation of the protein. The 
conserved disulfide bond (green) in each subunit conveys stability, while free cysteine 
residues (magenta) are implicated in irreversible unfolding 
Our latest published structures of Cu,ZnSOD (Shin et al. 2009) were derived from the 
eukaryotic thermophile Alvinella pompejana, a deep-sea thermal vent worm that we and 
others discovered contains particularly stable proteins (Burjanadze 2000; Henscheid et al. 
2005; Kashiwagi et al. 2010; Piccino et al. 2004). Alvinella pompejana Cu,ZnSOD allowed us to 
obtain both the first sub-angstrom resolution crystal structure of Cu,ZnSOD, and a co-
crystal structure with the H2O2 product. These structures revealed that the copper ion likely 
moves within the active site during catalysis (Shin et al. 2009). Structural and computational 
analyses showed that electrostatic guidance (Getzoff et al. 1992; Getzoff et al. 1983; Perry et 
al. 2010) aids catalysis, allowing Cu,ZnSOD to be one of the fastest enzymes known.  
Our initial structural studies on human Cu,ZnSOD were conducted prior to the discovery 
that ALS was correlated with mutations in Cu,ZnSOD (Deng et al. 1993; Rosen 1993). 
Greater than 130 Cu,ZnSOD mutations, occuring at ~70 of the 153 amino acids that comprise 
a single subunit of human Cu,ZnSOD (Figure 1), are now implicated in causing ALS; the 
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vast majority of these are autosomal dominant in inheritance. These Cu,ZnSOD associated 
ALS mutations also constitute the majority of ALS cases that have been genetically defined, 
approximately 20% of FALS cases and ~1-3% of SALS cases. Mapping of the ALS mutations 
onto the human Cu,ZnSOD structure prompted our suggestion of a ‘framework 
destabilization’ hypothesis (Deng et al. 1993). This destabilization hypothesis suggests that 
ALS SOD mutations promote local unfolding events in Cu,ZnSOD that can drive self-
aggregation and potentially aberrant interactions with other proteins, dysregulating the 
normal cellular functions of this highly abundant protein in neuronal cells.  
Alternative hypotheses include a gain of function mechanism, for example a change of SOD 
chemistry so that the enzyme performs other reactions (such as peroxidation and increased 
tyrosine nitration), or exhibits an increase or decrease in catalytic activity (Beckman et al. 
1993; Brown 1995; Crow et al. 1997; Rosen 1993; Wiedau-Pazos et al. 1996; Wong and 
Borchelt 1995; Zhang et al. 2002). However, support for these other hypotheses is unclear. 
Certain mutations are known to make a more active enzyme, while others produce a less 
active protein, and some have with relatively unchanged chemistry. Some mutations (such 
as H46R and H48Q) remove copper binding, rendering the protein non-catalytic, thus 
suggesting that gain of enzymatic function or increased activity is unlikely. Transgenic mice 
harboring SOD1 mutations present ALS-like symptoms (Gurney et al. 1994), but transgenic 
SOD1 knockout mice do not (Reaume et al. 1996). This indicates that a loss of normal 
catalytic activity or a gain of abnormal activity may not be important in propagating ALS. 
Also, activity-altering mutations would be expected to be focused in and around the active 
site, rather than occurring across the entire Cu,ZnSOD fold. 
Protein aggregates are observed within neural cells from Alzheimer’s, Huntington’s and 
Parkinson’s individuals (Dobson 2001; Soto 2001; Wanker 2000). Likewise, proteinaceous 
aggregates were discovered in neurons of ALS patients (Leigh et al. 1991). We observed in 
vitro that purified FALS A4V and H43R mutants form fibrous aggregates, and that two free 
cysteines within the protein are not required for this aggregation. These two ALS mutants 
bound Congo Red and Thioflavin T dyes that typically bind amyloid-like β-sheet structures 
(Figure 2) (DiDonato et al. 2003). Notably, the kinetics of forming aggregates and the 
binding affinity for dyes were more enhanced for the more clinically aggressive mutant A4V 
mutant. In cellular inclusions, aggregates were found to be immunoreactive for Cu,ZnSOD, 
and did not dissociate readily in the presence of detergents or reductants (Bruijn et al. 1998; 
Durham et al. 1997). Also, the detection of Cu,ZnSOD-containing inclusions often precedes 
ALS-like symptoms, and the aggregates are similar to Lewy bodies found in Parkinson’s 
disease (Johnston et al. 2000; Kato et al. 2001). 
ALS mutant SODs interact and/or co-precipitate with additional proteins to form the 
inclusions observed in cells from ALS patients; these inclusions resemble those characteristic 
of other neurodegenerative disease. These associated proteins include 1) proteins involved 
in stress response pathways, namely Derlin-1 (Nishitoh et al. 2008) and Rac1 (Harraz et al. 
2008), 2) chromogramin proteins associated with neurosectretory vesicles (Urushitani et al. 
2006), 3) the cytosolic chaperone Hsc70 (Wang et al. 2009), 4) the SOD copper chaperone 
(Kato et al. 2001), and 5) the dynein complex heavy chain, which is used in neural retrograde 
transport (Kieran et al. 2005; Zhang et al. 2007). Thus, local destabilizing SOD1 mutations, 
leading to interactions and/or co-precipitation of these proteins within aggregates, may 
impact normal cellular functions. It was also recently discovered that neural membrane 
fluidity was altered in transgenic ALS mice that harbor a FALS SOD mutation (Miana-Mena 
et al. 2011). The authors hypothesize that membranes may be altered through lipid 
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peroxidation, yet misfolded SODs may also play a role by interacting with membranes. 
Other hypotheses for the involvement of mutant SOD in ALS include disruption of the 
ubiquitin and proteosome system, altering mitochondrial function, playing a role in 
glutamatergic neurotransmission leading to excitotoxicity, and interference with axonal 
transport systems (Bastos et al. 2011; Kiernan et al. 2011; Ticozzi et al. 2011). Thus, we 
suggest that the framework destabilization hypothesis, unlike other suggested hypotheses, 
provides a unified mechanism for ALS mutant phenotype: This hypothesis encompasses the 
widespread distribution of ALS mutation sites within the protein, and is further supported 
by the observed in vitro aggregation results and the cellular analyses that are also in keeping 
with other aggregation-prone neurodegenerative diseases. 
 
 
Fig. 2. FALS SOD mutants promote the formation of filamentous aggregates. (A) Electron 
micrographs of H43R and A4V fibers reveals diameters of 2-15 nm implying a loss of dimer 
assembly specificity. Samples of H43R (top row), A4V (middle row) and wild-type (bottom 
row), all in the C6A, C111S SOD background lacking free Cys, were subjected to conditions 
designed to perturb the SOD fold. The scale bar = 40 nm. (B) Atomic force micrograph 
(phase mode) of large H43R bundles. Adapted from (DiDonato et al. 2003) 
3.1.2 FUS/TLS 
The FUS gene, representing the ALS6 subtype of amyotrophic lateral sclerosis, encodes the 
“fused in sarcoma” protein, initially characterized as one of the fusion proteins generated by 
carcinogenic oncogenes (Crozat et al. 1993; Rabbitts et al. 1993). The alternative name TLS 
stands for “translocation in liposarcoma”, and the gene product is often referred to as 
FUS/TLS, as we will do for the remainder of this chapter. FUS/TLS is a 526 amino acid 
protein of the TET family (which stands for Translocated in liposarcoma/Ewing's 
sarcoma/TATA-binding protein-associated factor 15). FUS/TLS binds both DNA and RNA, 
and like Cu,ZnSOD, is ubiquitously expressed. The protein is divided into distinct motifs 
and regions, which are responsible for different functions [see Figure 3 and the following 
reviews (Dormann and Haass 2011; Lagier-Tourenne and Cleveland 2009; Perry, Shin, and 
Tainer 2010)]. FUS/TLS plays a role in transcription activities within the cell via interactions 
with a variety of proteins, including transcription factors and hormone receptors (Cassiday 
and Maher 2002; Lagier-Tourenne and Cleveland 2009) (Cassiday and Maher 2002; Lagier-
Tourenne and Cleveland 2009; Law, Cann, and Hicks 2006). FUS/TLS may also function in 
DNA damage responses by binding to non-coding RNA elements transcribed by the 5’ 
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regulatory region of the cell-cycle kinase cyclin D1 gene. This binding event recruits 
FUS/TLS to interact with and inhibit CREB-binding protein and p300 histone 
acetelytransferase, further repressing cyclin D1-mediated transcription (Perry, Shin, and 
Tainer 2010). FUS/TLS has also been implicated in RNA processing, such as splicing, 
transport and maturation (Lagier-Tourenne and Cleveland 2009). In neurons, FUS/TLS is 
transported to dendritic spines upon activation of glutamate receptor mGluR5 (Fujii et al. 
2005).  
 
 
Fig. 3. Schematic diagrams of the FUS/TLS and TDP-43 proteins. Both proteins contain 
similar motifs, bind DNA and RNA, and are involved in both ALS and FTD. (Top) FUS/TLS 
contains QGSY- and Gly-rich regions, an RNA recognition motif (RRM) with a nuclear 
export signal (NES), a pair of RGG-motifs flanking a Zinc-finger (ZnF), and a nuclear 
localization signal (NLS). (Bottom) The TDP-43 protein has its NLS at the N-terminus, two 
RRM motifs with the latter containing an NES, and a C-terminal Gly-rich region. Red bars 
indicate ALS mutation sites, and red boxes indicate ALS hotspots that contain multiple ALS 
mutation sites. Numbers below indicate amino acid positions 
The FUS gene was implicated in ALS after the discovery that a locus within chromosome 16 
was linked to both autosomal dominant (Ticozzi et al. 2011; Vance et al. 2009) and recessive 
manifestations of the disease (Kwiatkowski et al. 2009). FUS mutations have since been 
identified in patients with sporadic ALS, and according to recent reviews [see (Kiernan et al. 
2011; Ticozzi et al. 2011)], FUS mutants are estimated to account for approximately 4-5% of 
FALS and 1% of SALS cases. Interestingly, mutations in FUS/TLS are also involved in FTD 
[see (Mackenzie, Rademakers, and Neumann 2010)]. The disease-promoting mechanisms in 
mutant FUS-mediated ALS are not understood, but aggregate formation has been observed 
(Deng et al. 2010; Vance et al. 2009; Dormann and Haass 2011). The FUS/TLS mutations 
tend to cluster mainly at the C-terminal glycine-rich region and NLS (Dormann and Haass 
2011; Lagier-Tourenne and Cleveland 2009; Perry, Shin, and Tainer 2010), instead of 
throughout the entire structure as observed in Cu,ZnSOD. Similar to Cu,ZnSOD mutant 
pathology is the observation that inclusions containing FUS/TLS are found within the 
cytosol within diseased neural cells (Dormann et al. 2010). Interestingly, NLS mutations that 
yield a greater concentration of FUS/TLS within the cytosol correlate with a more rapid 
onset and aggressiveness of the disease. Also, some of the most severe NLS mutations cause 
substitutions in amino acids required for an interaction with transportin, a nuclear import 
receptor (Dormann et al. 2010). Mutant cytosolic FUS/TLS may also be incorporated into 
stress granules that may serve as an inclusion precursor (Dormann and Haass 2011)). 
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Additionally, FUS/TLS has been predicted to contain prion-like regions within its amino-
acid sequence, which may also contribute to the formation of aggregates (Udan and Baloh 
2011). 
3.1.3 TDP-43 
TDP-43, named for binding to TAR DNA of the human immunodeficiency type 1 virus, is 
also a DNA and RNA binding protein like FUS/TLS. TDP-43 is encoded by the TARDBP 
gene, and is classified as the ALS10 subtype. TDP-43 is composed of 414 residues, and 
includes functional motifs shared with FUS/TLS (Figure 3). Functions for TDP-43 include 
transcriptional regulator (Abhyankar, Urekar, and Reddi 2007; Ayala, Misteli, and Baralle 
2008), and TDP-43 was also implicated in binding UG-repeat sequences, resulting in 
pathogenic consequences that include cystic fibrosis (Mantovani et al. 2007). Like FUS/TLS, 
TDP-43 has been implicated in both ALS and FTD pathology (Arai et al. 2006; Mackenzie, 
Rademakers, and Neumann 2010; Dormann and Haass 2011; Perry, Shin, and Tainer 2010). 
Presently, over 35 mutations in TDP-43 have been implicated in these two diseases, 
including ~0.5-2% of sporadic ALS cases (Arai et al. 2006) and ~3-5% of autosomal dominant 
FALS cases (Lagier-Tourenne and Cleveland 2009; Ticozzi et al. 2011). TDP-43 aggregates 
are also found within diseased neural cells, where the protein is found to be highly 
ubiquinated and phosphorylated, as well as being truncated (Arai et al. 2006; Neumann et 
al. 2006). These aggregates are generally localized to the cytoplasm, while nuclear levels of 
TDP-43 are significantly diminished. Interestingly, analysis of the aggregates suggests that 
these deposits are not composed of amyloid-like structures (Kwong et al. 2008). Cu,ZnSOD 
is not found within the TDP-43 or the FUS/TLS aggregates; however, a recent report states 
that mutant Cu,ZnSOD interacts with TDP-43 (Higashi et al. 2010), and was shown to co-
immunoprecipitate with FUS/TLS for a function in stabilizing histone deactylase 6 
(HDAC6) mRNA (Kim et al. 2010). ALS mutations in TDP-43 appear to enhance this 
interaction with FUS/TLS (Ling et al. 2010). Therefore, additional research is required to 
clearly define these provisional links between TDP-43, FUS/TLS and/or Cu,ZnSOD in ALS 
pathology.  
The majority of mutations found within TDP-43 ALS patients are missense mutations 
toward the C-terminal end of the protein, beginning at the glycine-rich segment. Recent 
research has identified the possibility that like FUS/TLS, TDP-43 also contains a prion-like 
element at its C-terminus. This region contains Gln and Asn residues similar to yeast Q/N 
prion domains. This represents yet another structural element that may initiate the 
formation of aggregates within ALS10 type cells. Currently, research on the function of 
TDP-43 and its roles in various pathologies including ALS and FTD is on the rise. Changes 
in TDP-43 structure and stability behind its ALS pathology may also influence the 
expression and activities of various cellular machinery within neural cells [see detailed 
reviews: (Dormann and Haass 2011; Lagier-Tourenne and Cleveland 2009; Lagier-Tourenne, 
Polymenidou, and Cleveland 2010; Perry, Shin, and Tainer 2010; Swarup et al. 2011)]. 
3.1.4 Other ALS subtypes 
Research is being initiated on the defective genes for the other, more rare, ALS subtypes [see 
more detailed reviews (Boillee, Vande Velde, and Cleveland 2006; Kiernan et al. 2011; 
Pasinelli and Brown 2006; Strong et al. 2007; Ticozzi et al. 2011) for further information on 
these lesser-characterized ALS subtypes]. Many proteins encoded by these ALS subtype 
genes share the ability to modulate gene expression and/or RNA metabolism; this includes  
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the ANG (ALS9) and SETX (ALS4) gene products, along with those of FUS/TLS, TDP-43 and 
SOD1 (Strong 2010). Also, the VAPB (ALS8) mutant shares the ability to form aggregates 
(Suzuki et al. 2009). Notably, the native alsin protein encoded by the ALS2 gene has been 
observed to offer protection against Cu,ZnSOD mutational effects in certain cells (Hadano et 
al. 2007). Many mutations in ALS2 are nonsense mutations that lead to truncations in the 
gene product, which can destabilize the protein, resulting in proteasomal degradation 
(Yamanaka et al. 2003). Another study suggests that alsin loss may cause neurons to be more 
vulnerable to excitotoxicity, via glutamate receptors (Lai et al. 2006). Co-localization has not 
yet been observed between Cu,ZnSOD and FUS/TLS or TDP-43. However, optineurin, 
which is encoded by OPTN and represents ALS12, does appear to colocalize with 
Cu,ZnSOD, FUS/TLS and TDP-43 [see (Ito et al. 2011)], and the interaction of optineruin 
with at least with the former two, appears to be mutually exclusive. A comprehensive study 
of a five generation family with ALS lead to the discovery that mutations in UBQLN2, 
which encodes the ubiquitin-like protein ubiquilin 2, cause dominant X-linked juvenile and 
adult-onset ALS and ALS/dementia (Deng et al. 2011). Also, excitingly, two very recent 
research findings have identified the largely uncharacterized locus 9p21 C9ORF72 gene 
product to be linked to a significant proportion of dominant cases of ALS/FTD (Renton et 
al, 2011; DeJesus-Hernandez et al. 2011) Thus, it currently appears that genetic lesions may 
lead to ALS by different pathways, and continued research will be needed to establish 
whether there are one, several or many more general mechanistic themes that lead to the 
ALS phenotypes. 
3.2 Other factors 
Non-genetic risk factors for ALS, including environmental factors and physical injury, are 
being actively pursued. Although the effects of these risks of ALS are difficult to 
deconvolute (e.g. the prevalence of ALS in athletes), the involvement of these factors may 
enhance underlying, genetic predispositions to the disease, or may indeed have a direct link 
to ALS. 
3.2.1 Diet/Lifestyle 
The role of diet in ALS was assessed when considerably higher prevalence levels of ALS 
were noted in certain Western Pacific populations (50-100-fold). Non-genetic causes for 
these ALS cases have been suggested to be due to high levels of β-methyl-amino-L-alanine. 
This non-standard amino acid is highly concentrated in a certain seed that is consumed by 
animals that provide food for the inhabitants of Guam (Bastos et al. 2011; Ince and Codd 
2005). A recent study has highlighted adverse effects from high levels of branched-chain 
amino acids (BCAAs) on the ion channels of mice. The researchers discovered an increased 
sodium current within motor neurons, resembling that observed in the transgenic 
Cu,ZnSOD G93A mouse model for ALS. The increased sodium current promotes 
hyperexcitability of the cells, which may lead to excitotoxicity, subsequent calcium influx 
and apoptosis (Carunchio et al. 2010; Manuel and Heckman 2011). BCAAs are commonly 
used as a supplement by athletes, and therefore might account for the increased incidence of 
ALS seen in Italian soccer (Chio et al. 2005) and American football (Abel 2007) players.  
Smoking was proposed as another potential risk factor for ALS (Kamel et al. 1999), and 
continues to provoke interest (Armon 2009). Several studies reported no ill effects of 
smoking on ALS (Schmidt et al. 2010) (Okamoto et al. 2009), others implicated a gender-
specific effect (Alonso et al. 2010), and a recent study of 832 ALS patients suggested smoking 
increased ALS incidence by ~1.4 fold (Wang et al. 2011). 
www.intechopen.com
 Advanced Understanding of Neurodegenerative Diseases 
 
428 
3.2.2 Injury and trauma 
Neuronal injury may result in excessive stimulation by α-amino-hydroxy-5-methylisoxasole-4 
propionic acid (AMPA), glutamate or kainite, leading to excitotoxcity and downstream 
apoptosis (Perry, Shin, and Tainer 2010; Beal 1992). Thus, head trauma may be linked to the 
increased incidence of ALS observed in Italian soccer players, American football players, 
and military personnel, all of whom more commonly have head injuries (Horner et al. 2008; 
Miranda et al. 2008). Other forms of trauma, such as electrical shock, have also been 
correlated to ALS [for a broader list and additional details, see the review by (Bastos et al. 
2011)].  
3.2.3 Environmental toxins 
Exposure to environmental toxins is actively investigated as a potential contributing factor 
to ALS. Several metals have been implicated in increased risk for ALS after occupational 
exposure to lead, residency in areas with high levels of selenium, and accidental contact 
with mercury (Bastos et al. 2011). Inhabitants of Guam who exhibit ALS-like symptoms have 
been exposed to potentially high levels of aluminum (Wicklund 2005). More complex 
molecules implicated in increased risk of ALS include formaldehyde, pesticides that are 
suspected to cause ALS in Italian soccer players, and chemical agents to which military 
personnel have been subjected. Yet, a causative effect between ALS and such factors is 
difficult to establish. One reason for this is the relatively small sample size in some of these 
studies. A second reason is the difficulty in deconvoluting which specific factor or 
combination of factors contributed to the disease, as in the case for the soccer players. Third, 
some of the ALS patients within the studies may have had an undetected genetic defect, and 
the additional environmental factor accelerated the course of the disease.  
4. Therapeutic progress 
The only approved treatment for ALS is riluzole, which functions to reduce glutamate-
induced excitotoxicity in ALS individuals, and is licensed by Sanofi-Aventis with the brand 
name Rilutek. Riluzole only modestly slows the progression of ALS, with a 9% gain in the 
probability of surviving one year, and a small beneficial effect for limb function, but not 
muscle strength (Miller et al. 2007). Several other drugs that gave positive results in animal 
models failed in human trials. However, additional clinical trials now underway are aimed 
at producing new ALS therapies by using varied strategic approaches that go beyond the 
modulation of glutamate levels [reviewed in (Zoccolella, Santamato, and Lamberti 2009)(see 
http://clinicaltrials.gov)]. Exciting progress in this regard includes the commencement of a 
phase I clinical trial by Neuralstem that aims to establish the safety and feasibility of using 
stem cells to treat ALS, by injecting these cells directly into the spinal cord (see 
http://neurology.emory.edu/ALS/Stem%20Cell.html). This development is based on 
initial studies showing that human fetal neuronal stem cells could delay the onset and 
progression in a rat model of ALS (Xu et al. 2006).  
The Northeast ALS consortium (NEALS), a non-profit consortium bringing together 
scientific and clinical investigators from now 97 institutions across in the United States, 
Puerto Rico, Canada and Ireland, forms a central component of many of the clinical trials 
(http://www.alsconsortium.org). For example, as part of NEALS, a stage III trial of 
ceftriaxone, which has been recently observed to modulate glutamate uptake, is being 
conducted by Massachusetts General Hospital with the National Institute of Neurological 
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Disorders and Stroke. Ceftriaxone is a semi-synthetic cephalosporin antibiotic, originally 
approved by the FDA for treating bacterial infections. Combination therapies are also being 
analyzed, including a phase II a trial by Phoenix Neurological Associates LTD of riluzole in 
conjunction with tretionin and pioglitazone. Tretinoin, used to treat acute promyelocytic 
leukemia (Sanz 2006), is a retinoic acid derivative, and as such may have neuroprotective 
properties (Choi et al. 2009; Lee et al. 2009). The oral anti-diabetic pioglitazone has anti-
inflammatory properties that showed positive responses in an ALS mouse model (Schutz et 
al. 2005). Tamoxifen is currently in stage II clinical trials for treating ALS, based on an 
observation by clinicians that an ALS patient also receiving tamoxifen for breast cancer had 
an unusually mild form of the disease (see http://www.alsa.org/research/clinical-
trials/trial-tamoxifen.html). Tamoxifen may also help protect cells from glutamate toxicity 
(Maenpaa et al. 2002) in addition to inhibiting protein kinase C mediated spinal 
inflammation and prolonging life expectancy in a mouse model of ALS (Traynor et al. 2006; 
Zoccolella, Santamato, and Lamberti 2009). 
Several other compounds with neuroprotective activities are undergoing clinical trials. These 
include rasagiline, which was reported to have neuroprotective properties in an ALS mouse 
model (Waibel et al. 2004). Rasagiline is currently used as a therapy for Parkinson’s disease, 
functioning as a selective inhibitor of monoamine oxidase B, and is now under phase II 
clinical trials for ALS treatment by the University of Kansas. Neuraltus Pharmaceuticals is 
targeting an anti-inflammatory response through transforming macrophage cells from a 
neurotoxic to a protective state, with the compound ‘NP001’ that is now in phase II clinical 
trials (see http://www.neuraltus.com). Biogen Idec and Knopp Biosciences have an 
interesting small molecule therapeutic, dexpramipexole, which also has a neuroprotective 
function, through increasing the efficiency of mitochondria in neurons (Gribkoff and Bozik 
2008). Dexpramipexole is the R(+) enantiomer of an already licensed compound, 
pramipexole, which is used for the treatment of both Parkinson’s disease and restless legs 
syndrome. Pramipexole functions as a non-ergot dopaminergic autoreceptor antagonist, but 
has dose-limiting side effects that include orthostatic hypotension and hallucination, due its 
dopaminergic receptor activity. Dempramipexole, on the other hand, has a much lower 
affinity for dopaminergic receptors, and in phase II trials was well tolerated at levels 
considerably higher than the maximum daily dose of pramipexole (Bozik et al. 2011). 
Dexpramipexole also showed positive trends in slowing functional decline and improving 
survivability in phase II, and is now undergoing a multi-national phase III study. 
Approaches specifically targeting Cu,ZnSOD include arimoclomol, a compound developed 
by CytRx corporation, that activates chaperones to perturb protein aggregation. 
Arimoclomol was observed to extend life in an ALS mutant Cu,ZnSOD mouse model 
(indirectly supporting the framework destabilization model for Cu,ZnSOD mutations), and 
is currently at the Phase II/III stage (Kalmar et al. 2008). Cornell University and the 
Muscular Dystrophy Association are studying pyrimethamine, an anti-malarial drug shown 
in one study to substantially reduce Cu,ZnSOD levels in mice (Lange 2008), although a 
separate study at the University of Massachusetts Medical School did not observe this 
pyrimethamine effect in either cells or animal models of disease (Wright et al. 2010). Moving 
away from small molecule based therapies, Isis Pharmaceuticals is taking an siRNA 
approach to combat FALS mutant Cu,ZnSOD, with Isis-SOD1RX entering into phase I 
clinical trials. Isis-SOD1RX is antisense oligonucleotide to SOD1 that is infused directly into 
the cerebral spinal fluid, due to an inability to pass the blood brain barrier. This siRNA was 
shown to reduce both Cu,ZnSOD protein and mRNA levels throughout the brain and spinal 
cord in animal models (Smith et al. 2006). 
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Other recent therapeutic approaches target muscle deficiencies in ALS. Cytokinetics 
developed ‘CK-2107357’, an activator of the fast skeletal muscle troponin complex, 
increasing cellular sensitivity to calcium, which results in an increase in skeletal muscle 
force and a decrease in the time to muscle fatigue. In phase IIa trials, CK-2107357 showed 
evidence of clinical effect, as well as being suitably safe and tolerated. Acceleron Pharma is 
developing ACE-031, a protein therapeutic that builds muscle and increases strength by 
inhibiting signaling through the activin type IIb cell surface receptor (Cadena et al. 2010). 
ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic 
lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-
related muscle loss (sarcopenia). An extended phase II clinical trial in Canada for Duchenne 
Muscular Dystrophy was recently terminated, and is pending further analysis of safety data. 
5. Future research 
Evidently, much work remains on all fronts from uncovering disease mechanisms to 
developing new therapies for ALS. The very recent publication determining that mutations 
in ubiquilin 2 are a cause of dominantly inherited X-linked ALS and ALS/dementia has 
opened up a new area of ALS research (Deng et al. 2011). Ubiquilin 2 functions as part of the 
protein degradation pathway, revealing pathological roles for this pathway in ALS and 
suggesting new therapeutic opportunities for treating ALS, since ubiquilin 2 was found in 
skein-like inclusions of a wide variety of ALS cases (Deng et al. 2011). Another area of 
important focus is improvement of animal models for ALS, as the utility of these has come 
into question (Benatar 2007; Bedlack, Traynor, and Cudkowicz 2007). One problem is that 
treatment in these animal models typical begins before the onset of disease symptoms, 
whereas this is not possible for ALS individuals, due to a lack of understanding of causative 
factors and potential differences in pathogenic mechanisms between SALS and FALS. 
Notably, when guidelines on improving animal study criteria were implemented, 
therapeutic benefits from a host of compounds that included ceftiaxone and even riluzole 
were no longer observed (Scott et al. 2008), further highlighting issues with the use and 
understanding of current models. Improved experimental ALS models will also be of use to 
further our understanding of the causative factors of SALS, such as potentially toxic effects 
of smoking on motor neurons. Future therapeutic studies also need to take into 
consideration overcoming problems within clinical trials, such as the small sample sizes and 
short durations of study, making assessment of milder effects that are expected with many 
of the therapeutics more challenging.  
Once key advance that is likely to influence the future direction of research is the generation 
of ALS stem cells from adult skin cells from an individual with ALS (Dimos et al. 2008). 
Now, stem cells from different patients can be isolated and used to grow different motor 
neuron cell lines for more detailed analyses, or potentially for high-throughput screening. 
6. Conclusions 
There has been some exciting progress in our understanding of ALS, including recent 
developments in the genetics and molecular mechanisms behind this most common form of 
motor neuron disease. New discoveries include the identification of two ALS-linked 
proteins, FUS/TLS and TDP-43, which are involved in DNA/RNA metabolism. However, 
we still have to clearly establish whether aggregation or loss of the wild-type functions of 
either of these two proteins is the underlying cause of the disease phenotype. Studies behind 
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the pathogenicity of Cu,ZnSOD mutations in ALS are also continuing, with the recent data 
supporting an initial concept that mutation-induced structural instability of the protein 
drives aggregation events, which ultimately prove toxic to the neuronal cell. Encouragingly, 
several distinct therapeutic strategies are in play aiming to at least delay the progression of 
the disease. These strategies range from small molecule inhibitors, some of which are in later 
stages of clinical trials, to siRNA and stem cell based approaches. We hope that the rapid 
pace of research findings and the ongoing clinical trials will shortly produce novel therapies 
that can help fight against this terrible disease. 
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